Two U.S. drug companies have halted trials of bapineuzumab, an experimental drug to treat Alzheimer’s Disease. The drug failed to produce any improvement in the symptoms of dementia sufferers.
Pfizer Inc. and Johnson & Johnson had been testing bapineuzumab, which had been designed to target brain plaques found in Alzheimer’s patients. Contrary to expectations, the drug failed to improve cognitive or functional ability in patients with the gene ApoE4, which tends to make people who have it more likely to develop the disease.
Alzheimer’s drug halted after trials. Healthcare Today UK, News, August 7th 2012. (Online).